352 related articles for article (PubMed ID: 29101303)
1. Pancreatic Ductal Adenocarcinoma Subtyping Using the Biomarkers Hepatocyte Nuclear Factor-1A and Cytokeratin-81 Correlates with Outcome and Treatment Response.
Muckenhuber A; Berger AK; Schlitter AM; Steiger K; Konukiewitz B; Trumpp A; Eils R; Werner J; Friess H; Esposito I; Klöppel G; Ceyhan GO; Jesinghaus M; Denkert C; Bahra M; Stenzinger A; Sprick MR; Jäger D; Springfeld C; Weichert W
Clin Cancer Res; 2018 Jan; 24(2):351-359. PubMed ID: 29101303
[No Abstract] [Full Text] [Related]
2. A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy.
Kaissis G; Ziegelmayer S; Lohöfer F; Steiger K; Algül H; Muckenhuber A; Yen HY; Rummeny E; Friess H; Schmid R; Weichert W; Siveke JT; Braren R
PLoS One; 2019; 14(10):e0218642. PubMed ID: 31577805
[TBL] [Abstract][Full Text] [Related]
3. CYP3A5 mediates basal and acquired therapy resistance in different subtypes of pancreatic ductal adenocarcinoma.
Noll EM; Eisen C; Stenzinger A; Espinet E; Muckenhuber A; Klein C; Vogel V; Klaus B; Nadler W; Rösli C; Lutz C; Kulke M; Engelhardt J; Zickgraf FM; Espinosa O; Schlesner M; Jiang X; Kopp-Schneider A; Neuhaus P; Bahra M; Sinn BV; Eils R; Giese NA; Hackert T; Strobel O; Werner J; Büchler MW; Weichert W; Trumpp A; Sprick MR
Nat Med; 2016 Mar; 22(3):278-87. PubMed ID: 26855150
[TBL] [Abstract][Full Text] [Related]
4. Biomarkers for subtypes of pancreatic ductal adenocarcinoma.
Venkatesan P
Lancet Oncol; 2017 Dec; 18(12):e718. PubMed ID: 29129444
[No Abstract] [Full Text] [Related]
5. HNF1A inhibition induces the resistance of pancreatic cancer cells to gemcitabine by targeting ABCB1.
Lu Y; Xu D; Peng J; Luo Z; Chen C; Chen Y; Chen H; Zheng M; Yin P; Wang Z
EBioMedicine; 2019 Jun; 44():403-418. PubMed ID: 31103629
[TBL] [Abstract][Full Text] [Related]
6. Prognostic relevance of molecular subtypes and master regulators in pancreatic ductal adenocarcinoma.
Janky R; Binda MM; Allemeersch J; Van den Broeck A; Govaere O; Swinnen JV; Roskams T; Aerts S; Topal B
BMC Cancer; 2016 Aug; 16():632. PubMed ID: 27520560
[TBL] [Abstract][Full Text] [Related]
7. Keratin 17 identifies the most lethal molecular subtype of pancreatic cancer.
Roa-Peña L; Leiton CV; Babu S; Pan CH; Vanner EA; Akalin A; Bandovic J; Moffitt RA; Shroyer KR; Escobar-Hoyos LF
Sci Rep; 2019 Aug; 9(1):11239. PubMed ID: 31375762
[TBL] [Abstract][Full Text] [Related]
8. Perspectives in the treatment of pancreatic adenocarcinoma.
Cid-Arregui A; Juarez V
World J Gastroenterol; 2015 Aug; 21(31):9297-316. PubMed ID: 26309356
[TBL] [Abstract][Full Text] [Related]
9. Subtype-Discordant Pancreatic Ductal Adenocarcinoma Tumors Show Intermediate Clinical and Molecular Characteristics.
Topham JT; Karasinska JM; Lee MKC; Csizmok V; Williamson LM; Jang GH; Denroche RE; Tsang ES; Kalloger SE; Wong HL; O'Kane GM; Moore RA; Mungall AJ; Notta F; Loree JM; Wilson JM; Bathe O; Tang PA; Goodwin R; Knox JJ; Gallinger S; Laskin J; Marra MA; Jones SJM; Renouf DJ; Schaeffer DF
Clin Cancer Res; 2021 Jan; 27(1):150-157. PubMed ID: 33051307
[TBL] [Abstract][Full Text] [Related]
10. CFTR Expression Analysis for Subtyping of Human Pancreatic Cancer Organoids.
Hennig A; Wolf L; Jahnke B; Polster H; Seidlitz T; Werner K; Aust DE; Hampe J; Distler M; Weitz J; Stange DE; Welsch T
Stem Cells Int; 2019; 2019():1024614. PubMed ID: 31191661
[TBL] [Abstract][Full Text] [Related]
11. Pancreatic cancer survival analysis defines a signature that predicts outcome.
Raman P; Maddipati R; Lim KH; Tozeren A
PLoS One; 2018; 13(8):e0201751. PubMed ID: 30092011
[TBL] [Abstract][Full Text] [Related]
12. Linc00675 is a novel marker of short survival and recurrence in patients with pancreatic ductal adenocarcinoma.
Li DD; Fu ZQ; Lin Q; Zhou Y; Zhou QB; Li ZH; Tan LP; Chen RF; Liu YM
World J Gastroenterol; 2015 Aug; 21(31):9348-57. PubMed ID: 26309360
[TBL] [Abstract][Full Text] [Related]
13. Pancreatic cancer stem cells may define tumor stroma characteristics and recurrence patterns in pancreatic ductal adenocarcinoma.
Askan G; Sahin IH; Chou JF; Yavas A; Capanu M; Iacobuzio-Donahue CA; Basturk O; O'Reilly EM
BMC Cancer; 2021 Apr; 21(1):385. PubMed ID: 33836674
[TBL] [Abstract][Full Text] [Related]
14. Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy.
Amer AM; Zaid M; Chaudhury B; Elganainy D; Lee Y; Wilke CT; Cloyd J; Wang H; Maitra A; Wolff RA; Varadhachary G; Overman MJ; Lee JE; Fleming JB; Tzeng CW; Katz MH; Holliday EB; Krishnan S; Minsky BD; Herman JM; Taniguchi CM; Das P; Crane CH; Le O; Bhosale P; Tamm EP; Koay EJ
Cancer; 2018 Apr; 124(8):1701-1709. PubMed ID: 29370450
[TBL] [Abstract][Full Text] [Related]
15. A common genetic variation of melanoma inhibitory activity-2 labels a subtype of pancreatic adenocarcinoma with high endoplasmic reticulum stress levels.
Kong B; Wu W; Valkovska N; Jäger C; Hong X; Nitsche U; Friess H; Esposito I; Erkan M; Kleeff J; Michalski CW
Sci Rep; 2015 Feb; 5():8109. PubMed ID: 25657029
[TBL] [Abstract][Full Text] [Related]
16. Gene expression profiling of 1200 pancreatic ductal adenocarcinoma reveals novel subtypes.
Zhao L; Zhao H; Yan H
BMC Cancer; 2018 May; 18(1):603. PubMed ID: 29843660
[TBL] [Abstract][Full Text] [Related]
17. High nuclear Survivin expression as a poor prognostic marker in pancreatic ductal adenocarcinoma.
Zhou L; Lu J; Liang ZY; Zhou WX; Yuan D; Li BQ; You L; Guo JC; Zhao YP
J Surg Oncol; 2018 Dec; 118(7):1115-1121. PubMed ID: 30261114
[TBL] [Abstract][Full Text] [Related]
18. CXCR4--A Prognostic and Clinicopathological Biomarker for Pancreatic Ductal Adenocarcinoma: A Meta-Analysis.
Krieg A; Riemer JC; Telan LA; Gabbert HE; Knoefel WT
PLoS One; 2015; 10(6):e0130192. PubMed ID: 26091099
[TBL] [Abstract][Full Text] [Related]
19. A novel hotspot and rare somatic mutation p.A138V, at TP53 is associated with poor survival of pancreatic ductal and periampullary adenocarcinoma patients.
Saha G; Singh R; Mandal A; Das S; Chattopadhyay E; Panja P; Roy P; DeSarkar N; Gulati S; Ghatak S; Ghosh S; Banerjee S; Roy B; Ghosh S; Chaudhuri D; Arora N; Biswas NK; Sikdar N
Mol Med; 2020 Jun; 26(1):59. PubMed ID: 32552660
[TBL] [Abstract][Full Text] [Related]
20. HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Kalisz M; Bernardo E; Beucher A; Maestro MA; Del Pozo N; Millán I; Haeberle L; Schlensog M; Safi SA; Knoefel WT; Grau V; de Vas M; Shpargel KB; Vaquero E; Magnuson T; Ortega S; Esposito I; Real FX; Ferrer J
EMBO J; 2020 May; 39(9):e102808. PubMed ID: 32154941
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]